| First trimester screening for Down syndrome | ||
|---|---|---|
| Prev | ||
Adekunle O, Gopee A, el Sayed M & Thilaganathan B (1999) Increased first trimester nuchal translucency: pregnancy and infant outcomes after routine screening for Down"s syndrome in an unselected antenatal population. Br J Radiol 72: 457–460.
Aitken DA, McCaw G, Crossley JA, Berry E, Connor JM, Spencer K & Macri JN (1993) First-trimester biochemical screening for fetal chromosome abnormalities and neural tube defects. Prenat Diagn 13: 681–689.
Aitken DA, McKinnon D, Crossley J, Graham GW, Berry E, Spencer K, Macri JN & Connor JM (1994) Changes in the maternal serum concentrations of PAPP-A and SP1 in Down"s syndrome pregnancies between the first and second trimesters. J Med Genet 31: 170.
Aitken DA, Wallace EM, Crossley JA, Swanston IA, van Pareren Y, van Maarle M, Groome NP, Macri JN & Connor JM (1996) Dimeric inhibin A as a marker for Down"s syndrome in early pregnancy. N Engl J Med 334: 1231–1236.
Antolin E, Comas C, Torrents M, Munoz A, Figueras F, Echevarria M, Cararach M & Carrera JM (2001) The role of ductus venosus blood flow assessment in screening for chromosomal abnormalities at 10-16 weeks of gestation. Ultrasound Obstet Gynecol 17: 295–300.
Ascheim S & Zondek B (1927) Hypophysenworderlappen hormon und ovarialhormon im Harn von Schwangeren. Klin Wochenschr 6: 1322–1324.
Audibert F, Dommergues M, Benattar C, Taieb J, Thalabard J-C & Frydman R (2001) Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study. Ultrasound Obstet Gynecol 18: 26–31.
Bahado-Singh RO, Oz AU, Shahabi S, Mahoney MJ, Baumgarten A & Cole L (2000) Comparison of urinary hyperglycosylated human chorionic gonadotropin concentration with the serum triple screen for Down syndrome detection in high-risk pregnancies. Am J Obstet Gynecol 183: 1114–1118.
Barkai G, Goldman B, Ries L, Chaki R, Dor J & Cuckle H (1996) Down"s syndrome screening marker levels following assisted reproduction. Prenat Diagn 16: 1111–1114.
Benacerraf BR, Frigoletto FD & Laboda LA (1985) Sonographic diagnosis of Down syndrome in the second trimester. Am J Obstet Gynecol 153: 49–52.
Berry E, Aitken D, Crossley JA, Macri JN & Connor JM (1995) Analysis of maternal serum alpha-fetoprotein and free beta human chorionic gonadotrophin in the first trimester: implications for Down"s syndrome screening. Prenat Diagn 15: 555–565.
Berry E, Aitken DA, Crossley JA, Macri JN & Connor JM (1997) Screening for Down"s syndrome: changes in marker levels and detection rates between first and second trimesters. Br J Obstet Gynaecol 104: 811–817.
Bersinger NA, Brizot ML, Johnson A, Snijders RJ, Abbott J, Schneider H & Nicolaides KH (1994) First trimester maternal serum pregnancy-associated plasma protein A and pregnancy-specific beta 1-glycoprotein in fetal trisomies. Br J Obstet Gynaecol 101: 970–974.
Bersinger NA, Marguerat P, Pescia G & Schneider H (1995) Pregnancy-associated plasma protein A (PAPP-A): measurement by highly sensitive and spesific enzyme immunoassay, importance of first-trimester serum determinations and stability studies. Reprod Fertil Dev 7: 1419–1423.
Bewley S, Roberts LJ, Mackinson AM & Rodeck CH (1995) First trimester fetal nuchal translucency: problems with screening the general population. 2. Br J Obstet Gynaecol 102: 386–388.
Biagiotti R, Brizzi L, Periti E, d"Agata A, Vanzi E & Cariati E (1998) First trimester screening for Down"s syndrome using maternal serum PAPP-A and free beta-hCG in combination with fetal nuchal translucency thickness. Br J Obstet Gynaecol 105: 917–920.
Biagiotti R, Periti E, Brizzi L, Vanzi E & Cariati E (1997) Comparison between two methods of standardization for gestational age differences in fetal nuchal translucency measurement in first-trimester screening for trisomy 21. Ultrasound Obstet Gynecol 9: 248–252.
Bilardo CM, Muller MA, Zikulnig L, Schipper M & Hecher K (2001a) Ductus venosus studies in fetuses at high risk for chromosomal or heart abnormalities: relationship with nuchal translucency measurement and fetal outcome. Ultrasound Obstet Gynecol 17: 288–294.
Bilardo CM, Muller MA & Pajkrt E (2001b) Outcome of fetuses with increased nuchal translucency. Curr Opin Obstet Gynecol 13: 169–174.
Bindra R, Heath V, Liao AW, Spencer K & Nicolaides KH (2002) One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies. Ultrasound Obstet Gynecol 20: 219–225.
Bischof P, DuBerg S, Herrmann WL & Sizonenko PC (1982) Amniotic fluid and plasma concentrations of pregnancy-associated plasma protein A (PAPP-A) throughout pregnancy: comparison with other fetoplacental products. Br J Obstet Gynaecol 89: 358–363.
Bischof P & Tseng L (1986) In vitro release of pregnancy-associated plasma protein A (PAPP-A) by human endometrial cells. Am J Reprod Immunol 10: 139–142.
Bogart MH, Pandian MR & Jones OW (1987) Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn 7: 623–630.
Borrell A, Antolin E, Costa D, Farre MT, Martinez JM & Fortuny A (1998) Abnormal ductus venosus blood flow in trisomy 21 fetuses during early pregnancy. Am J Obstet Gynecol 179: 1612–1617.
Brady AF, Pandya PP, Yuksel B, Greenough A, Patton MA & Nicolaides KH (1998) Outcome of chromosomally normal livebirths with increased fetal nuchal translucency at 10-14 weeks" gestation. J Med Genet 35: 222–224.
Braithwaite JM, Morris RW & Economides DL (1996) Nuchal translucency measurements: frequency distribution and changes with gestation in a general population. Br J Obstet Gynaecol 103: 1201–1204.
Brambati B, Cislaghi C, Tului L, Alberti E, Amidani M, Colombo U & Zuliani G (1995) First-trimester Down"s syndrome screening using nuchal translucency: a prospective study in patients undergoing chorionic villus sampling. Ultrasound Obstet Gynecol 5: 9–14.
Brambati B, Macintosh MC, Teisner B, Maguiness S, Shrimanker K, Lanzani A, Bonacchi I, Tului L, Chard T & Grudzinskas J (1993) Low maternal serum level of pregnancy associated plasma protein (PAPP-A) in the first trimester in association with abnormal fetal karyotype. Br J Obstet Gynaecol 100: 324–326.
Braunstein G, Rasor J, Adler D, Danzer H & Wade ME (1976) Serum human chorionic gonadotropin levels throughout normal pregnancy. Am J Obstet Gynecol 126: 678–681.
Bray I & Wright D (1998) Estimating the spontaneous loss of Down syndrome fetuses between the time of chorionic villus sampling, amniocentesis and livebirth. Prenat Diagn 18: 1045–1054.
Brizot M, Carvalho M, Liao AW, Reis N & Armbruster-Moraes E (2001) First -trimester screening for chromosomal abnormalities by fetal nuchal translucency in a Brazilian population. Ultrasound Obstet Gynecol 18: 652–655.
Brizot ML, Hyett JA, McKie AT, Bersinger NA, Farzaneh F & Nicolaides KH (1996) Gene expression of human pregnancy-associated plasma protein-A in placenta from trisomic pregnancies. Placenta 17: 33–36.
Brizot ML, Snijders RJ, Bersinger NA, Kuhn P & Nicolaides KH (1994) Maternal serum pregnancy-associated plasma protein A and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancy. Obstet Gynecol 84: 918–922.
Brizot ML, Snijders RJ, Butler J, Bersinger NA & Nicolaides KH (1995) Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy. Br J Obstet Gynaecol 102: 127–132.
Canick JA, Knight GJ, Palomaki GE, Haddow JE, Cuckle HS & Wald NJ (1988) Low second trimester maternal serum unconjugated oestriol in pregnancies with Down"s syndrome. Br J Obstet Gynaecol 95: 330–333.
Caughey A, Kuppermann M, Norton ME & Washington AE (2002) Nuchal translucency and first trimester biochemical markers for Down syndrome screening: A cost-effectiveness analysis. Am J Obstet Gynecol 187: 1239–1245.
Chen M, Lam YH, Tang MHY, Lee CP, Sin SY, Tang R, Wong HS & Wong SF (2002) The effect of ethnic origin on nuchal translucency at 10-14 weeks of gestation. Prenat Diagn 22: 576–578.
Christiansen M & Larsen S (2002) An increase in cost-effectiveness of first trimester maternal screening programmes for fetal chromosome anomalies is obtained by contingent testing. Prenat Diagn 22: 482–486.
Cicero S, Bindra R, Rembouskos G, Spencer K & Nicolaides KH (2003) Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks. Prenat Diagn 23: 306–310.
Cicero S, Curcio P, Papageorgiou C, Sonek J & Nicolaides KH (2001) Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study. Lancet 358: 1665–1667.
Cole L, Omrani A, Cermik D, Singh R & Mahoney MJ (1998) Hyperglycosylated hCG, a potential alternative to hCG in Down syndrome screening. Prenat Diagn 18: 926–933.
Cole L, Rinne K, Mahajan S, Oz AU, Shahabi S, Mahoney MJ & Bahado-Singh RO (1999a) Urinary screening tests for fetal Down syndrome: I. Fresh beta-core fragment. Prenat Diagn 19: 340–350.
Cole L, Shahabi S, Oz U, Rinne K, Omrani A, Bahado-Singh RO & Mahoney MJ (1999b) Urinary screening tests for fetal Down syndrome: II. Hyperglycosylated hCG. Prenat Diagn 19: 351–359.
Conover CA, Faessen GF, Ilg KE, Chandrasekher YA, Christiansen M, Overgaard MT, Oxvig C & Giudice LC (2001) Pregnancy-associated plasma protein-A is the insulin-like growth factor binding protein-4 protease secreted by human ovarian granulosa cells and is a marker of dominant follicle selection and the corpus luteum. Endocrinology 142: 2155.
Crossley J, Aitken DA, Waugh S, Kelly T & Connor JM (2002a) Maternal smoking: age distribution, levels of alpha-fetoprotein and human chorionic gonadotrophin, and effect on detection of Down syndrome pregnancies in second-trimester screening. Prenat Diagn 22: 247–255.
Crossley JA, Aitken DA, Cameron AD, McBride E & Connor JM (2002b) Combined ultrasound and biochemical screening for Down`s Syndrome in the first trimester: a Scottish multicentre study. Br J Obstet Gynaecol 109: 667–676.
Cuckle H (2001) Integrating antenatal Down"s syndrome screening. Curr Opin Obstet Gynecol 13: 175–181.
Cuckle H, Iles R & Chard T (1994) Urinary beta-core human chorionic gonadotrophin: a new approach to Down"s syndrome screening. Prenat Diagn 14: 953–958.
Cuckle H, Shahabi S, Sehmi I, Jones R & Cole L (1999) Maternal urine hyperglycosylated hCG in pregnancies with Down syndrome. Prenat Diagn 19: 918–920.
Cuckle H & Van Lith JM (1999) Appropriate biochemical parameters in first-trimester screening for Down syndrome. Prenat Diagn 19: 505–512.
Cuckle H, Wald N, Barkai G, Fuhrmann W, Altland K & Brambati B (1988) First trimester biochemical screening for Down syndrome. Lancet 2: 851–852.
Cuckle HS, Holding S, Jones R, Groome NP & Wallace EM (1996) Combining inhibin A with existing second-trimester markers in maternal serum screening for Down"s syndrome. Prenat Diagn 16: 1095–1100.
Cuckle HS, Wald NJ, Densem JW, Royston P, Knight GJ, Haddow JE & Palomaki GE (1990) The effect of smoking in pregnancy on maternal serum alpha-fetoprotein, unconjugated oestriol, human chorionic gonadotrophin, progesterone and dehydroepiandrosterone sulphate levels. Br J Obstet Gynaecol 97: 272–274.
De Biasio P, Siccardi M, Volpe G, Famularo L, Santi F & Canini S (1999) First-trimester screening for Down syndrome using nuchal translucency measurement with free beta-hCG and PAPP-A between 10 and 13 weeks of pregnancy--the combined test. Prenat Diagn 19: 360–363.
de Graaf IM, Cuckle HS, Pajkrt E, Leschot NJ, Bleker OP & Van Lith JM (2000) Co-variables in first trimester maternal serum screening. Prenat Diagn 20: 186–189.
de Graaf IM, Pajkrt E, Bilardo CM, Leschot NJ, Cuckle HS & Van Lith JM (1999) Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency. Prenat Diagn 19: 458–462.
de Graaf IM, Tijmstra T, Bleker OP & Van Lith JM (2002) Womens preference in Down syndrome screening. Prenat Diagn 22: 624–629.
Demir R, Demir AY & Yinanc M (1994) Structural changes in placental barrier of smoking mother. A quantitative and ultrastructural study. Path Res Pract 190: 656–667.
Down LJ (1866) Observations on an ethnic classification of idiots. Clin Lectures and Reports, London Hospital 3: 259–262.
Esterman A, Finlay TH & Dancis J (1996) The effect of hypoxia on term trophoblast: hormone synthesis and release. Placenta 17: 217–222.
Ferriman EL, Sehmi IK, Jones R & Cuckle HS (1999) The effect of smoking in pregnancy on maternal serum inhibin A levels. Prenat Diagn 19: 372–374.
Forest JC, Masse J & Moutquin JM (1997) Screening for Down syndrome during first trimester: a prospective study using free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. Clin Biochem 30: 333–338.
Fox H (1970) Effect of hypoxia on trophoblast in organ culture. A morphologic and autoradiographic study. Am J Obstet Gynecol 107: 1058–1064.
Frishman GN, Canick JA, Hogan JW, Hackett RJ, Kellner LH & Saller DN, Jr. (1997) Serum triple-marker screening in in vitro fertilization and naturally conceived pregnancies. Obstet Gynecol 90: 98–101.
Gasiorek-Wiens A, Tercanli S, Kozlowski P, Kossakiewicz A, Minderer S & Meyberg H (2001) Screening for trisomy 21 by fetal nuchal translucency and maternal age: a multicenter project in Germany, Austria and Switzerland. Ultrasound Obstet Gynecol 18: 645–648.
Ghezzi F, Raio L, Di Naro E, Franchi M, Buttarelli M & Schneider H (2002) First-trimester umbilical cord diameter: a novel marker of fetal aneuploidy. Ultrasound Obstet Gynecol 19: 235–239.
Ghi T, Huggon IC, Zosmer N & Nicolaides KH (2001) Incidence of major structural cardiac defects associated with increased nuchal translucency but normal karyotype. Ultrasound Obstet Gynecol 18: 610–614.
Gilbert R, Augood C, Gupta R, Ades AE, Logan S, Sculpher M & van der Meulen JHP (2001) Screening for Down´s syndrome: effects, safety, and cost effectiveness of first and second trimester strategies. Bmj 323: 423–425.
Greco P, Loverro G, Vimercati A, Marzullo A, Caruso G & Selvaggi L (1996) Pathological significance of first-trimester fetal nuchal oedema. Prenat Diagn 16: 503–509.
Hackshaw AK & Wald NJ (2001a) Assessment of the value of reporting partial screening results in prenatal screening for Down syndrome. Prenat Diagn 21: 737–740.
Hackshaw AK & Wald NJ (2001b) Inaccurate estimation of risk in second trimester serum screening for Down syndrome among women who have already had first trimester screening. Prenat Diagn 21: 741–746.
Haddow JE (1998) Antenatal screening for Down"s syndrome: where are we and where next? Lancet 352: 336–337.
Haddow JE, Palomaki GE, Knight GJ, Williams J, Miller WA & Johnson A (1998) Screening of maternal serum for fetal Down"s syndrome in the first trimester. N Engl J Med 338: 955–961.
Haddow JE, Palomaki GE, Knight GJ, Williams J, Pulkkinen A, Canick JA, Saller DN, Jr. & Bowers GB (1992) Prenatal screening for Down"s syndrome with use of maternal serum markers. N Engl J Med 327: 588–593.
Hafner E, Schuchter K, Liebhart E & Philipp K (1998) Results of routine fetal nuchal translucency measurement at 10-13 weeks in 4,233 unselected pregnant women. Prenat Diagn 18: 29–34.
Halliday J, Watson LF, Lumley J, Danks DM & Sheffield LJ (1995) New estimates of Down syndrome risks at chorionic villus sampling, amniocentesis and live birth in women of advanced maternal age from a uniquely defined population. Prenat Diagn 15: 455–465.
Hecher K (2001) Assessment of ductus venosus flow during the first and early second trimesters: what can we expect? Ultrasound Obstet Gynecol 14: 285–287.
Hecht C & Hook E (1994) The imprecision in rates of Down syndrome by 1-year maternal age intervals: a critical analysis of rates used in biochemical screening. Prenat Diagn 14: 729–738.
Heikkilä A, Heinonen S & Kirkinen P (2000) Maternal serum second trimester AFP and hCG in pregnancies with placenta previa. Prenat Diagn 20: 100–102.
Heinonen S, Ryynänen M, Kirkinen P, Hippeläinen M & Saarikoski S (1996) Effect of in vitro fertilization on human chorionic gonadotropin serum concentrations and Down"s syndrome screening. Fertil Steril 66: 398–403.
Herman A, Dreazen E, Tovbin J, Weinraub Z, Bukovsky I & Maymon R (2002a) Comparison between disclosure and non-disclosure approaches for trisomy 21 screening tests. Hum Reprod 17: 1358–1362.
Herman A, Dreazen E, Herman A, Batukan C, Holzgreve W & Tercanli S (2002b) Bedside estimation of Down syndrome risk during first-trimester ultrasound screening. Ultrasound Obstet Gynecol 20: 468–475.
Hiippala A, Eronen M, Taipale P, Salonen R & Hiilesmaa V (2001) Fetal nuchal translucency and normal chromosomes: a long-term follow-up study. Ultrasound Obstet Gynecol 18: 18–22.
Hook EB, Mutton DE, Ide R, Alberman E & Bobrow M (1995) The natural history of Down syndrome conceptuses diagnosed prenatally that are not electively terminated. Am J Hum Genet 57: 875–881.
Hyett J, Moscoso G & Nicolaides K (1997) Abnormalities of the heart and great arteries in first trimester chromosomally abnormal fetuses. Am J Hum Genet 69: 207–216.
Hyett J, Perdu M, Sharland G, Snijders R & Nicolaides KH (1999) Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study. Bmj 318: 81–85.
Hyett JA, Noble PL, Snijders RJ, Montenegro N & Nicolaides KH (1996a) Fetal heart rate in trisomy 21 and other chromosomal abnormalities at 10-14 weeks of gestation. Ultrasound Obstet Gynecol 7: 239–244.
Hyett JA, Sebire NJ, Snijders RJ & Nicolaides KH (1996b) Intrauterine lethality of trisomy 21 fetuses with increased nuchal translucency thickness. Ultrasound Obstet Gynecol 7: 101–103.
Jauniaux E & Burton GJ (1992) The effect of smoking in pregnancy on early placental morphology. Obstet Gynecol 79: 645–648.
Jauniaux E, Gavrill P, Khun P, Kurdi W, Hyett J & Nicolaides KH (1996) Fetal heart rate and umbilico-placental Doppler flow velocity waveforms in early pregnancies with a chromosomal abnormality and/or an increased nuchal translucency thickness. Hum Reprod 11: 435–439.
Johnson MP, Johnson A, Holzgreve W, Isada NB, Wapner RJ, Treadwell MC, Heeger S & Evans MI (1993) First-trimester simple hygroma: cause and outcome. Am J Obstet Gynecol 168: 156–161.
Kadir RA & Economides DL (1997) The effect of nuchal translucency measurement on second-trimester biochemical screening for Down"s syndrome. Ultrasound Obstet Gynecol 9: 244–247.
Koivurova S, Hartikainen AL, Karinen L, Gissler M, Hemminki E, Martikainen H, Tuomivaara L & Järvelin MR (2002) The course of pregnancy and delivery and the use of maternal healthcare services after standard IVF in Northern Finland 1990-1995. Hum Reprod 17: 2897–2903.
Kornman LH, Morssink LP, Beekhuis JR, De Wolf BT, Heringa MP & Mantingh A (1996) Nuchal translucency cannot be used as a screening test for chromosomal abnormalities in the first trimester of pregnancy in a routine ultrasound practice. Prenat Diagn 16: 797–805.
Kornman LH, Morssink LP, Wortelboer MJ, Beekhuis JR, De Wolf BT, Pratt JJ & Mantingh A (1997) Maternal urinary beta-core hCG in chromosomally abnormal pregnancies in the first trimester. Prenat Diagn 17: 135–139.
Krantz DA, Hallahan TW, Orlandi F, Buchanan P, Larsen JW, Jr. & Macri JN (2000) First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol 96: 207–213.
Krantz DA, Larsen JW, Buchanan PD & Macri JN (1996) First-trimester Down syndrome screening: free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. Am J Obstet Gynecol 174: 612–616.
Lam YH, Tang MHY, Lee CP, Sin SY, Tang R, Wong HS & Wong SF (2001) The effect of fetal gender on nuchal translucency at 10-14 weeks of gestation. Prenat Diagn 21: 627–629.
Lam Y, Lee CP, Sin SY, Tang R, Wong HS, Wong SF & et al (2002) Comparison and integration of first trimester fetal nuchal translucency and second trimester maternal serum screening for fetal Down syndrome. Prenat Diagn 22: 730–735.
Lam Y, Yeung WSB, Tang MHY, Ng E, So W & Ho P (1999) Maternal serum alphafetoprotein and human chorionic gonadotrophin in pregnancies conceived after intracytoplasmic sperm injection and conventional in vitro fertililization. Hum Reprod 14: 2120–2123.
Liao AW, Heath V, Kametas N, Spencer K & Nicolaides KH (2001) First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction. Hum Reprod 16: 1501–1504.
Liao AW, Snijders R, Geerts L, Spencer K & Nicolaides KH (2000) Fetal heart rate in chromosomally abnormal fetuses. Ultrasound Obstet Gynecol 16: 610–613.
Lin T, Halbert SP, Kiefer D, Spellacy WN & Gall S (1974) Characterisation of four human pregnancy associated plasma proteins. Am J Obstet Gynecol 118: 223–236.
Macintosh MC, Iles R, Teisner B, Sharma K, Chard T, Ward R & Grudzinskas JG (1994) Maternal serum human chorionic gonadotrophin and pregnancy-associated plasma protein A, markers for fetal Down syndrome at 8-14 weeks. Prenat Diagn 14: 203–208.
Macintosh MC, Wald N, Chard T, Hansen J, Mikkelsen M, Therkelsen A, Petersen G & Lundsteen C (1995) Selective miscarriage of Down"s syndrome fetuses in women aged 35 and older. Br J Obstet Gynaecol 102: 798–801.
Malone F, Berkowitz R, Canick J & D"Alton M (2000) First-trimester screening for aneuploidy: Research or standard of care. Am J Obstet Gynecol 182: 490–496.
Marana HR, Andrade JM, Martins GA, Silva JS, Sala MA & Cunha SP (1998) A morphometric study of maternal smoking on apoptosis in the syncytiotrophoblast. Int J Gynaecol Obstet 61: 21–27.
Martinez JM, Comas C, Ojuel J, Borrell A, Puerto B & Fortuny A (1996) Fetal heart rate patterns in pregnancies with chromosomal disorders or subsequent fetal loss. Obstet Gynecol 87: 118–121.
Matias A, Gomes C, Flack N, Montenegro N & Nicolaides KH (1998) Screening for chromosomal abnormalities at 10-14 weeks: the role of ductus venosus blood flow. Ultrasound Obstet Gynecol 12: 380–384.
Matias A, Huggon IC, Areias JC, Montenegro N & Nicolaides KH (1999) Cardiac defects in chromosomally normal fetuses with abnormal ductus venosus blood flow at 10-14 weeks. Ultrasound Obstet Gynecol 14: 307–310.
Matias A & Montenegro N (2001) Ductus venosus blood flow in chromosomally abnormal fetuses at 11 to 14 weeks of gestation. Sem Perinatol 25: 32–37.
Mavrides E, Cobian-Sanchez F, Tekay A, Moscoso G, Campbell S, Thilaganathan B & Carvalho JS (2001a) Limitations of using first-trimester nuchal translucency measurement in routine screening for major congenital heart defects. Ultrasound Obstet Gynecol 17: 106–110.
Mavrides E, Holden D, Bland JM, Tekay A & Thilaganathan B (2001b) Intraobserver and interobserver variability of transabdominal Doppler velocimetry measurements of the fetal ductus venosus between 10 and 14 weeks of gestation. Ultrasound Obstet Gynecol 17: 306–310.
Mavrides E, Sairam S, Hollis B & Thilaganathan B (2002) Screening for aneuploidy in the first trimester by assessment of blood flow in the ductus venosus. Br J Obstet Gynaecol 109: 1015–1019.
Maymon R, Dreazen E, Rozinsky S, Bukovsky I, Weinraub Z & Herman A (1999) Comparison of nuchal translucency measurement and mid-gestation serum screening in assisted reproduction versus naturally conceived singleton pregnancies. Prenat Diagn 19: 1007–1011.
Maymon R, Jauniaux E, Cohen O, Dreazen E, Weinraub Z & Herman A (2000) Pregnancy outcome and infant follow-up of fetuses with abnormally increased first trimester nuchal translucency. Hum Reprod 15: 2023–2027.
Maymon R & Shulman A (2001) Comparison of triple serum screening and pregnancy outcome in oocyte donation versus IVF pregnancies. Hum Reprod 16: 691–695.
Maymon R & Shulman A (2002) Serial first- and second-trimester Down"s syndrome screening tests among IVF-versus naturally-conceived singletons. Hum Reprod 17: 1081–1085.
Merkatz IR, Nitowsky HM, Macri JN & Johnson WE (1984) An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 148: 886–894.
Metzenbauer M, Hafner E, Schuchter K & Philipp K (2002) First-trimester placental volume as a marker for chromosomal anomalies: preliminary results from an unselected population. Ultrasound Obstet Gynecol 19: 240–242.
Michailidis G & Economides DL (2001) Nuchal translucency measurement and pregnancy outcome in karyotypically normal fetuses. Ultrasound Obstet Gynecol 17: 102–105.
Michailidis G, Spencer K & Economides DL (2001) The use of nuchal translucency measurement and second trimester biochemical markers in screening for Down"s syndrome. Br J Obstet Gynaecol 108: 1047–1052.
Morris J, Wald N & Watt HC (1999) Fetal Loss in Down syndrome Pregnancies. Prenat Diagn 19: 142–145.
Nadel A, Bromley B & Benacerraf BR (1993) Nuchal thickening or cystic hygromas in first- and early second-trimester fetuses: prognosis and outcome. Obstet Gynecol 82: 43–48.
Neveux LM, Palomaki GE, Knight GJ & Haddow JE (1996) Multiple marker screening for Down syndrome in twin pregnancies. Prenat Diagn 16: 29–34.
Nicolaides KH, Azar G, Byrne D, Mansur C & Marks K (1992) Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. Bmj 304: 867–869.
Nicolaides KH, Brizot ML & Snijders RJ (1994) Fetal nuchal translucency: ultrasound screening for fetal trisomy in the first trimester of pregnancy. Br J Obstet Gynaecol 101: 782–786.
Nicolaides K, Sebire NJ & Snijders R (1999) The 11-14 -week scan. The diagnosis of fetal abnormalities. Parthenon Publishing, New York, London, p 21.
Noble PL, Snijders RJ, Abraha HD, Sherwood RA & Nicolaides KH (1997a) Maternal serum free beta-hCG at 10 to 14 weeks of gestation in trisomic twin pregnancies. Br J Obstet Gynaecol 104: 741–743.
Noble PL, Wallace EM, Snijders RJ, Groome NP & Nicolaides KH (1997b) Maternal serum inhibin-A and free beta-hCG concentrations in trisomy 21 pregnancies at 10 to 14 weeks of gestation. Br J Obstet Gynaecol 104: 367–371.
O´Brien J, Dvorin E, Yaron Y, Ayoub M, Johnson MP, Hume RF, Jr. & Evans MI (1997) Differential increases in AFP, hCG, and uE3 in twin pregnancies: Impact on attempts to quantify Down syndrome screening calculations. Am J Med Genet 73: 109–112.
Orlandi F, Damiani G, Hallahan TW, Krantz DA & Macri JN (1997) First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency. Ultrasound Obstet Gynecol 10: 381–386.
Orlandi F, Rossi C, Allegra A, Krantz D, Hallahan T, Orlandi E & Macri JN (2002) First trimester screening with free beta hCG, PAPP-A and nuchal translucency in pregnancies conceived with assisted reproduction. Prenat Diagn 22: 718–721.
Orvos H & Wayda (2002) Increased nuchal translucency and congenital heart defects in euploid fetuses. The Szeged experience. Eur J Obstet Gynecol Reprod Biol 101: 124–128.
Pajkrt E, Mol BW, Bleker OP & Bilardo CM (1999) Pregnancy outcome and nuchal translucency measurements in fetuses with a normal karyotype. Prenat Diagn 19: 1104–1108.
Pajkrt E, Van Lith JM, Mol BW, Bleker OP & Bilardo CM (1998) Screening for Down"s syndrome by fetal nuchal translucency measurement in a general obstetric population. Ultrasound Obstet Gynecol 12: 163–169.
Paladini D, Tartaglione A, Agangi A, Teodoro A, Forleo F, Borghese A & Martinelli P (2000) The association between congenital heart disease and Down syndrome in prenatal life. Ultrasound Obstet Gynecol 15: 104–108.
Palomaki GE, Knight GJ, Haddow JE, Canick JA, Wald NJ & Kennard A (1993) Cigarette smoking and levels of maternal serum alpha-fetoprotein, unconjugated estriol, and hCG: impact on Down syndrome screening. Obstet Gynecol 81: 675–678.
Pandya PP, Goldberg H, Walton B, Riddle A, Shelley S, Snijders RJ & Nicolaides KH (1995a) The implementation of first-trimester scanning at 10-13 weeks" gestation and the measurement of fetal nuchal translucency thickness in two maternity units. Ultrasound Obstet Gynecol 5: 20–25.
Pandya PP, Kondylios A, Hilbert L, Snijders RJ & Nicolaides KH (1995b) Chromosomal defects and outcome in 1015 fetuses with increased nuchal translucency. Ultrasound Obstet Gynecol 5: 15–19.
Pandya PP, Snijders R, Psara N, Hilbert L & Nicolaides KH (1996) The prevalence of non-viable pregnancy at 10-13 weeks of gestation. Ultrasound Obstet Gynecol 7: 170–173.
Perheentupa A, Ruokonen A, Tuomivaara L, Ryynänen M & Martikainen H (2002) Maternal serum beta-HCG and alphafetoprotein concentrations in singleton pregnancies following assisted reproduction. Hum Reprod 17: 794–797.
Pertl B & Bianchi DW (2001) Fetal DNA in maternal plasma: emerging clinical applications. Obstet Gynecol 98: 483–490.
Petrou S, Henderson J, Roberts T & Martin M-A (2000) Recent economic evaluations of antenatal screening: a systematic review and critique. J Med Screening 7: 59–73.
Prefumo F, De Biasio P & Venturini PL (2001) Reproducibility of ductus venosus Doppler flow measurements at 11-14 weeks of gestation. Ultrasound Obstet Gynecol 17: 301–305.
Reynolds T (2000) Down"s syndrome screening: a controversial test, with more controversy to come! J Clin Pathol 53: 893–898.
Ribbert LS, Kornman LH, De Wolf BT, Simons AH, Jansen CA, Beekhuis JR & Mantingh A (1996) Maternal serum screening for fetal Down syndrome in IVF pregnancies. Prenat Diagn 16: 35–38.
Rozenberg P, Malagrida L, Cuckle H, Durand-Zalenski I, Nisand I, Audibert F & et al (2002) Down"s syndrome screening with nuchal translucency at 12+0 - 14+0 weeks and maternal serum markers at 14+1 - 17+0 weeks: a prospective study. Hum Reprod: 1093–1098.
Räty R, Virtanen A, Koskinen P, Anttila L, Forsstrom J & Laitinen P (2002) Serum free beta-hCG and alpha-fetoprotein levels in IVF, ICSI and frozen embryo transfer pregnancies in maternal mid-trimester serum screening for Down syndrome. Hum Reprod 17: 481–484.
Savoldelli G, Binkert F, Achermann J & Schmid W (1993) Ultrasound screening for chromosomal anomalies in the first trimester of pregnancy. Prenat Diagn 13: 513–518.
Schuchter K, Hafner E, Stangl G, Metzenbauer M, Höfinger D & Philipp K (2002) The first trimester "combined test" for the detection of Down syndrome pregnancies in 4939 unselected pregnancies. Prenat Diagn 22: 211–215.
Schwärzler P, Carvalho JS, Senat M-V, Masroor T, Campbell S & Ville Y (1999) Screening for fetal aneuploidies and fetal cardiac abnormalities by nuchal translucency thickness measurement at 10-14 weeks of gestation as part of routine antenatal care in an unselected population. Br J Obstet Gynaecol 106: 1029–1034.
Sebire NJ, Spencer K, Noble PL, Hughes K & Nicolaides KH (1997a) Maternal serum alpha-fetoprotein in fetal neural tube and abdominal wall defects at 10 to 14 weeks of gestation. Br J Obstet Gynaecol 104: 849–851.
Sebire N, Snijders R, Davenport M, Greenough A & Nicolaides KH (1997b) Fetal nuchal translucency thickness at 10-14 weeks`gestation and congenital diaphragmatic hernia. Obstet Gynecol 90: 943–946.
Sebire N, Snijders R, Hughes K, Sepulveda W & Nicolaides KH (1996) Screening for trisomy 21 in twin pregnancies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Br J Obstet Gynaecol 103: 999–1003.
Sebire N, Souka A, Skentou H, Geerts L & Nicolaides KH (2000) Early prediction of severe twin-to-twin transfusion syndrome. Hum Reprod 15: 2008–2010.
Senat M-V, De Keersmaecker B, Audibert F, Montcharmont G, Frydman R & Ville Y (2002) Pregnancy outcome in fetuses with increased nuchal translucency and normal karyotype. Prenat Diagn 22: 345–349.
Shackley P, McGuire A, Boyd PA, Dennis J, Fitchett M & Kay J (1993) An economic appraisal of alternative pre-natal screening programmes for Down´s syndrome. J Public Health Med 15: 175–184.
Sheldon T & Simpson J (1991) Appraisal of a new scheme for prenatal screening for Down`s syndrome. Bmj 302: 1133–1136.
Simola K (1998) Kromosomisairaudet. In Aula P, Kääriäinen H & Leisti J (eds) Perinnöllisyyslääketiede, 1. ed. Kustannus Oy Duodecim, Helsinki, p 136–152.
Simpson J & Sharland G (2000) Nuchal translucency and congenital heart defects: heart failure or not? Ultrasound Obstet Gynecol 16: 30–36.
Snijders RJ, Noble P, Sebire N, Souka A & Nicolaides KH (1998) UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 352: 343–346.
Snijders RJ, Sundberg K, Holzgreve W, Henry G & Nicolaides KH (1999) Maternal age- and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol 13: 167–170.
Souka A, Krampl E, Bakalis S, Heath V & Nicolaides KH (2001) Outcome of pregnancy in chromosomally normal fetuses with increased nuchal translucency in the first trimester. Ultrasound Obstet Gynecol 18: 5–8.
Souka A, Snijders R, Novakov A, Soares W & Nicolaides KH (1998) Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of gestation. Ultrasound Obstet Gynecol 11: 391–400.
Spencer K (1998) The influence of smoking on maternal serum AFP and free beta hCG levels and the impact on screening for Down syndrome. Prenat Diagn 18: 225–234.
Spencer K (1999) The influence of smoking on maternal serum PAPP-A and free beta hCG levels in the first trimester of pregnancy. Prenat Diagn 19: 1065–1066.
Spencer K (2000) Screening for trisomy 21 in twin pregnancies in the first trimester using free beta-hCG and PAPP-A, combined with fetal nuchal translucency thickness. Prenat Diagn 20: 91–95.
Spencer K (2001a) Screening for trisomy 21 in twin pregnancies in the first trimester: does chorionicity impact on maternal serum free beta hCG or PAPP-A levels? Prenat Diagn 21: 715–717.
Spencer K (2001b) What is the true fetal loss rate in pregnancies affected by trisomy 21 and how does this influence whether first trimester detection rates are superior to those in the second trimester? Prenat Diagn 21: 788–789.
Spencer K, Liao AW, Ong CY, Geerts L & Nicolaides KH (2001) Maternal serum levels of dimeric inhibin A in pregnancies affected by trisomy 21 in the first trimester. Prenat Diagn 21: 441–444.
Spencer K & Nicolaides KH (2003) Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience. Br J Obstet Gynaecol 110: 276–280.
Spencer K, Noble P, Snijders RJ & Nicolaides KH (1997) First-trimester urine free beta hCG, beta core, and total oestriol in pregnancies affected by Down"s syndrome: implications for first-trimester screening with nuchal translucency and serum free beta hCG. Prenat Diagn 17: 525–538.
Spencer K, Salonen R & Muller F (1994) Down"s syndrome screening in multiple pregnancies using alpha-fetoprotein and free beta hCG. Prenat Diagn 14: 537–542.
Spencer K, Souter V, Tul N, Snijders R & Nicolaides KH (1999) A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 13: 231–237.
Spencer K, Spencer C, Power M, Dawson C & Nicolaides KH (2003) Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. Br J Obstet Gynaecol 110: 281–286.
Szabo J & Gellen J (1990) Nuchal fluid accumulation in trisomy-21 detected by vaginosonography in first trimester. Lancet 336: 1133.
Szabó J, Gellén J & Szemere G (1995) First trimester ultrasound screening for fetal aneuploidies in women over 35 and under 35 years of age. Ultrasound Obstet Gynecol 5: 161–163.
Taipale P, Hiilesmaa V, Salonen R & Ylöstalo P (1997) Increased nuchal translucency as a marker for fetal chromosomal defects. N Engl J Med 337: 1654–1658.
Tan SL, Doyle P, Campbell S, Beral V, Rizk B, Brinsden P, Mason B & Edwards RG (1992) Obstetric outcome of in vitro fertilization pregnancies compared with normally conceived pregnancies. Am J Obstet Gynecol 167: 778–784.
Theodoropoulos P, Lolis D, Papageorgiou C, Papaioannou S, Plachouras N & Makrydimas G (1998) Evaluation of first-trimester screening by fetal nuchal translucency and maternal age. Prenat Diagn 18: 133–137.
Thilaganathan B, Sairam S, Michailidis G & Wathen NC (1999) First trimester nuchal translucency: effective routine screening for Down"s syndrome. Br J Radiol 72: 946–948.
Thilaganathan B, Slack A & Wathen NC (1997) Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down"s syndrome. Ultrasound Obstet Gynecol 10: 261–264.
Van Lith JM, Visser GH, Mantingh A & Beekhuis JR (1992) Fetal heart rate in early pregnancy and chromosomal disorders. Br J Obstet Gynaecol 99: 741–744.
Van Vugt JM, Tinnemans BW & Zalen-Sprock RM (1998) Outcome and early childhood follow-up of chromosomally normal fetuses with increased nuchal translucency at 10-14 weeks" gestation. Ultrasound Obstet Gynecol 11: 407–409.
Vintzileos AM, Ananth CV, Fisher AJ, Smulian JC, Day-Salvatore D & Beazoglou T (1998) An economic evaluation of first-trimester genetic sonography for prenatal detection of Down syndrome. Obstet Gynecol 91: 535–539.
von Kaisenberg CS, Brand-Saberi B, Christ B, Vallian S, Farzaneh F & Nicolaides KH (1998) Collagen type VI gene expression in the skin of trisomy 21 fetuses. Obstet Gynecol 91: 319–323.
Wald N, Cuckle H, Wu TS & George L (1991) Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down"s syndrome. Br J Obstet Gynaecol 98: 905–908.
Wald N, Huttly WJ & Hackshaw AK (2003) Antenatal screening for Down"s syndrome with the quadruple test. Lancet 361: 835–836.
Wald N, Watt HC & Hackshaw AK (1999a) Integrated screening for Down"s syndrome based on tests performed during the first and second trimesters. N Engl J Med 341: 461–467.
Wald NJ, Brock DJ & Bonnar J (1974) Prenatal diagnosis of spina bifida and anencephaly by maternal serum-alpha-fetoprotein measurement. A controlled study. Lancet 1: 765–767.
Wald NJ, George L, Smith D, Densem JW & Petterson K (1996) Serum screening for Down"s syndrome between 8 and 14 weeks of pregnancy. International Prenatal Screening Research Group. Br J Obstet Gynaecol 103: 407–412.
Wald NJ & Hackshaw AK (1997) Combining ultrasound and biochemistry in first-trimester screening for Down"s syndrome. Prenat Diagn 17: 821–829.
Wald NJ, White N, Morris JK, Huttly WJ & Canick JA (1999b) Serum markers for Down"s syndrome in women who have had in vitro fertilization: implications for antenatal screening. Br J Obstet Gynaecol 106: 1304–1306.
Wallace EM, Grant VE, Swanston IA & Groome NP (1995) Evaluation of maternal serum dimeric inhibin A as a first-trimester marker of Down"s syndrome. Prenat Diagn 15: 359–362.
Weinans M, Butler S, Mantingh A & Cole L (2000) Urinary hyperglycosylated hCG in first trimester screening for chromosomal abnormalities. Prenat Diagn 20: 976–978.
Wojdemann K, Larsen SO, Shalmi A, Sundberg K, Christiansen M & Tabor A (2001) First trimester screening for Down syndrome and assisted reproduction: no basis for concern. Prenat Diagn 21: 563–565.
Zimmermann R, Hucha A, Savoldelli G, Binkert F, Achermann J & Grudzinskas JG (1996) Serum parameters and nuchal translucency in first trimester screening for fetal chromosomal abnormalities. Br J Obstet Gynaecol 103: 1009–1014.
Zoppi MAP (2002) First-Trimester Ductus venosus Velocimetry in Relation to Nuchal Translucency Thickness and Fetal Karyotype. Fet Diagn Ther 17: 52–57.
Zoppi MAP, Ibba RM, Floris M & Monni G (2001) Fetal nuchal translucency screening in 12 495 pregnancies in Sardinia. Ultrasound Obstet Gynecol 18: 649–651.